{
    "nct_id": "NCT00083590",
    "title": "A Multi-Center, Double-Blind, Placebo-Controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function",
    "status": "COMPLETED",
    "last_update_time": "2008-02-19",
    "description_brief": "The present study will evaluate the safety and efficacy of the Chinese herb huperzine A in the treatment of Alzheimer's disease (AD) in a randomized controlled trial of its effect on cognitive function.",
    "description_detailed": "Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata. There is evidence that huperzine A may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use. In addition, huperzine A has antioxidant and neuroprotective properties that suggest that it may be useful as a disease-modifying treatment for Alzheimer's disease (AD). The drug is currently available as a nutraceutical in this country, and is being used by some U.S. clinicians to treat AD. However, there have been no controlled clinical trials outside China assessing its toxicity and efficacy. The present study will evaluate huperzine A in the treatment of AD in a randomized controlled trial of its effect on cognitive function.\n\nThe primary aim of this multicenter, double-blind, placebo-controlled therapeutic Phase II trial is to determine whether treatment with huperzine A 200\u00b5g twice a day improves cognitive function in individuals with AD. Secondary aims of this study are to: a) determine whether treatment with huperzine A 400\u00b5g twice a day improves cognitive function in individuals with AD; b) determine the effect of huperzine A treatment on global clinical status, activities of daily living, and behavior in AD; c) evaluate the tolerability of huperzine A treatment at dosages of 200\u00b5g twice a day and 400\u00b5g twice a day in AD; and d) determine the relationship between blood cholinesterase activity and cognitive function in individuals with AD treated with huperzine A. A total of 150 participants will be randomly assigned to three groups of equal size. This will allow a comparison of huperzine A 200\u00b5g twice a day, huperzine A 400\u00b5g twice a day, and placebo. The primary outcome measures will be the change in score on the ADAScog at the 16 week visit. Secondary outcome measures include the ADCS clinical global impression of change (CGIC) (Schneider et al 1997) and activities of daily living (ADL) (Galasko et al 1997) scales, and the Neuropsychiatric Inventory (Cummings 1997). Volunteers must be able to participate in the study for 24 weeks and make 9 visits to the trial site.\n\nAt the end of the double-blind study, participants will be invited to continue huperzine A treatment for 6 months in an open-label extension phase. Participants will receive 200\u00b5g of huperzine A twice a day for six consecutive months, and will be assessed at 3-month intervals (months 6, 9, and 12, with month 6 assessments coinciding with the final visit of the double-blind phase).",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "huperzine A"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The intervention is huperzine A, a natural alkaloid from the Chinese club moss Huperzia serrata that acts as an acetylcholinesterase (AChE) inhibitor \u2014 i.e., it increases acetylcholine to produce symptomatic cognitive effects rather than directly modifying amyloid/tau pathology. \ue200cite\ue202turn0search1\ue202turn0search4\ue201",
        "Act: Extracted details from the trial description: randomized, double-blind, placebo-controlled study assessing huperzine A for improvement in cognitive function. Huperzine A is consistently described in clinical literature as a natural AChE inhibitor studied as a symptomatic cognitive enhancer in AD; randomized trials and meta-analyses report modest cognitive/ADL benefits in some studies but note limited methodological quality. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Reflect: Classification rationale \u2014 by the provided category definitions, huperzine A is best classified as a 'cognitive enhancer' because (1) it is used to improve cognitive function in AD, and (2) its mechanism (AChE inhibition) provides symptomatic cholinergic enhancement rather than targeting core AD pathology (amyloid or tau). This distinguishes it from 'disease-targeted small molecule' as defined (which would target pathology). Meta-analyses and RCTs support symptomatic cognitive outcomes but do not indicate disease modification. \ue200cite\ue202turn0search2\ue202turn0search6\ue201",
        "Web search results used (key sources): Neurology multicenter RCT summary (huperzine A trials). \ue200cite\ue202turn0search0\ue201; PubMed entries and trial/meta-analysis summaries describing huperzine A as a natural acetylcholinesterase inhibitor and summarizing RCT/meta-analysis evidence for cognitive benefit and safety. \ue200cite\ue202turn0search1\ue202turn0search3\ue202turn0search2\ue201",
        "Notes / ambiguity: The compound is a small alkaloid molecule but its clinical use and mechanism reviewed in the literature place it as a symptomatic cognitive enhancer rather than a disease-modifying agent; some trials show modest benefit but overall evidence quality has been judged limited. If you want, I can provide direct quotes or full-text links for any of the cited studies. \ue200cite\ue202turn0search3\ue202turn0search6\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests huperzine A, a natural alkaloid that acts as an acetylcholinesterase (AChE) inhibitor to increase synaptic acetylcholine and produce symptomatic cognitive enhancement rather than targeting core AD pathology (amyloid or tau). \ue200cite\ue202turn0search5\ue202turn0search4\ue201",
        "Act: Extracted details \u2014 randomized, double\u2011blind, placebo\u2011controlled therapeutic trial of huperzine A for cognitive improvement. Huperzine A\u2019s primary mechanism in clinical literature is AChE inhibition (cholinergic enhancement), placing it within neurotransmitter/cholinergic modulation rather than a disease\u2011modifying category. \ue200cite\ue202turn0search6\ue202turn0search0\ue201",
        "Reflect: Classification check \u2014 CADRO\u2019s nearest fit for symptomatic cholinergic drugs and agents that modulate neurotransmission is D) Neurotransmitter Receptors (covers interventions acting on neurotransmitter systems, including cholinergic enhancers). No evidence in the description suggests amyloid/tau, inflammation, synaptic neuroprotection as the primary target, nor a multi\u2011target mechanism; therefore D is the most specific CADRO category. \ue200cite\ue202turn0search4\ue202turn0search0\ue201",
        "Web search results (key sources used): 1) PLOS ONE systematic review/meta\u2011analysis of huperzine A in AD (summarizes RCTs and symptomatic effects). \ue200cite\ue202turn0search0\ue201 2) Neurology phase II multicenter trial of huperzine A in mild\u2011moderate AD (trial details, dosing, outcomes). \ue200cite\ue202turn0search5\ue202turn0search6\ue201 3) Earlier/meta\u2011analytic reviews showing modest cognitive/ADL benefits with generally mild cholinergic adverse events but limited methodological quality. \ue200cite\ue202turn0search4\ue202turn0search7\ue201"
    ]
}